NanoSyrinx is discovery-stage synthetic biology company focused on the development of nanosyringes which inject bioactive proteins and peptides through cell membranes for precision intracellular targeting.
NanoSyrinx’s technology is built upon a fully customizable, proprietary genetic platform that has been incorporated into industry-scalable expression systems. The platform produces a novel class of protein nanosyringes which deliver bioactive peptide and protein payloads directly to the interiors of targeted cells. The platform has been validated with a range of payloads including short peptides and complex enzymes.
Current estimates are that <20% of know human proteins have been drugged and the vast majority of these are on the cell surface or circulating outside of the human cell. There is a vast untapped market opportunity to deliver the latest generation of biologic drugs (e.g. antibodies, nanobodies and gene editing therapies) to targets inside the cell. Market demand has been validated through extensive customer discovery during the ICURe programme and a bespoke market report delivered by IP Pragmatics under the BBSRC Pathfinder Scheme. The market opportunity for nanotechnology-enabled drug delivery is estimated to be $136bn by 2021, growing at 12.5%.
NanoSyrinx will operate a hybrid business model, delivering both in house and partnered programmes aimed at developing the next generation of precision medicines to address areas of unmet medical need.
Chairman: Steve Taylor
CEO & Co-founder: Dr Joe Healey
Scientific Advisor & Co-founder: Prof. Nick Waterfield
Business Advisor: Dr James Lapworth
Contact: [email protected] | https://www.nanosyrinx.com